AUG 21, 2013 10:00 AM PDT

Genomic Approaches to Discover Biomarkers of Drug Response in Cancer

C.E. Credits: CE
Speaker

Abstract

Massively parallel sequencing technology has proven to enable the identification of driver genetic alterations in patients' tumors that may be suppressed by targeted therapies. Through retrospective analysis of clinical specimens, one can discover genomic biomarkers that predict outcomes and therapeutic response. Longitudinal profiling of multiple tumors in a single patient can reveal factors that influence tumor progression and drug resistance. Finally, prospective sequencing of patient specimens, when coupled with complementary radiology and histology based imaging, can enhance the clinical diagnosis and treatment of cancer patients. For increasingly lower costs, one can profile clinically relevant genes for mutations, copy number alterations, and structural rearrangements, with high detection sensitivity in low purity or multi-clonal tumor tissue. Advances in target capture, sample multiplexing, and profiling of formalin-fixed paraffin embedded (FFPE) specimens have further established the clinical utility of next generation sequencing. However, challenges remain in the application of these techniques to the analysis of clinical samples. In addition to the technical challenge of analyzing scant amounts of FFPE tissue, one must overcome the biological challenges of aneuploidy and heterogeneity inherent to the genetics of cancer. I will discuss different strategies for sequencing clinical samples, including different sequencing platforms, capture methods, and breadth of testing (i.e. targeted versus comprehensive approaches). I will describe examples in which our group has performed massively parallel sequencing on clinically annotated tumor specimens to identify genomic biomarkers of drug response and resistance. Finally, I will describe additional challenges in prospectively applying these techniques for clinical diagnosis involving bioinformatics, clinical interpretation, regulatory compliance, and ethics.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
DEC 09, 2021 11:00 AM PST
C.E. CREDITS
DEC 09, 2021 11:00 AM PST
Date: December 09, 2021 Time: 11:00am (PDT), 2:00pm (EDT) The burden of antimicrobial resistance (AMR) has been acknowledged worldwide by leading health institutes. Besides the need for new...
AUG 21, 2013 10:00 AM PDT

Genomic Approaches to Discover Biomarkers of Drug Response in Cancer

C.E. Credits: CE


Show Resources
Loading Comments...
Show Resources